The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multi-modal AI modeling to predict clinical trial outcomes and benchmarks pan-RAS versus KRAS G12D inhibition in KRAS G12D–mutant PDAC.
 
Marc Robert de Massy
Employment - Mnemo Therapeutics; Orakl Oncology
 
Jerome Caron
Employment - Orakl Oncology
 
Jean Bouteiller
Employment - Orakl Oncology
 
Anna-Rose Gryspeert
Employment - Orakl Oncology
 
Lélia Polit
Employment - Orakl Oncology
Patents, Royalties, Other Intellectual Property - Orakl Oncology; WhiteLab Genomics
 
Rafal Pietrzak
Employment - Orakl Oncology
 
Mateo Longarini
Employment - Orakl Oncology
 
Cartry Jerome
Stock and Other Ownership Interests - Orakl Oncology
 
Jacques Mathieu
No Relationships to Disclose
 
Sabrina Bedja
No Relationships to Disclose
 
Alice Boileve
Travel, Accommodations, Expenses - Ipsen; Merck; Pfizer
 
Michel Ducreux
Employment - Sandoz (I)
Stock and Other Ownership Interests - ABCELY
Honoraria - Amgen; Bayer; Pierre Fabre; Roche/Genentech; TERUMO
Consulting or Advisory Role - Abbvie (Inst); Abcely; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS GmbH & Co. KG; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; Merck Serono; MSD; Novartis; Pierre Fabre; Rafael Pharmaceuticals; Revolution Medicines; Roche; Scandion Oncology; SERVIER; Servier; Sotio; Zymeworks
Speakers' Bureau - Amgen; AstraZeneca; Bayer; GlaxoSmithKline; HalioDx; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; SERVIER
Research Funding - Keocyt (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Serono; Pierre Fabre; Roche; SERVIER
(OPTIONAL) Uncompensated Relationships - Astellas Pharma; Revolution Medicines
 
Fanny Jaulin
Employment - Orakl Oncology
Stock and Other Ownership Interests - Orakl Oncology
 
Gustave Ronteix
Employment - Orakl Oncology
Stock and Other Ownership Interests - Orakl Oncology